A practical reference on Stenabolic: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== WTO resources === "DS26: European Communities — Measures Concerning Meat and Meat Products (Hormones)". World Trade Organization. "DS48: European Communities — Measures Concerning Meat and Meat Products (Hormones) (Canada)". World Trade Organization. "DS320: United States — Continued Suspension of Obligations in the EC — Hormones Dispute". World Trade Organization. "DS321: Canada — Continued Suspension of Obligations in the EC — Hormones Dispute". World Trade Organization.
NOS Events – The NOS is also responsible for broadcasting live special events, such as breaking news, weddings of the Dutch royal family, and the Dutch elections. (This department was called NOS Actueel, but that name is defunct since on 1 January 2006 NOS RTV changed its corporate identity) Nieuwsuur (Newshour) – Co-produced with the NTR, the NOS provides news and political affairs coverage for NPO 2's nightly hour-long news magazine programme.
== Toxicity == Ingestion of lobeline may cause nausea, vomiting, diarrhea, coughing, dizziness, visual disturbances, hearing disturbances, mental confusion, weakness, slowed heart rate, increased blood pressure, increased breathing rate, tremors, and seizures. Lobeline has a narrow therapeutic index: the potentially beneficial dose of lobeline is very close to the toxic dose.
Sources: en.wikipedia.org
=== 28 March === German Minister of Defence Boris Pistorius stated that 18 Leopard 2A6 tanks had arrived in Ukraine. Ukrainian Defence spokeswoman Iryna Zolotar confirmed the arrival of British Challenger 2 tanks.
=== Wound Healing Center === The SOMC Wound Healing Center treats diabetic ulcers, lower leg ulcers, press ulcers, bone infection, gangrene, skin tears or lacerations, radiation burns, post-operation wounds and infections and failed or compromised skin grafts. Services offered include:
The album fused together the Reids' two primary influences: the guitar noise of the Stooges and the Velvet Underground with the pop songwriting and melodies of the Beach Boys, The Shangri-Las and Phil Spector; In fact, the album's opening song, "Just Like Honey," borrows Hal Blaine's famous drum intro from The Ronettes 1963 classic, "Be My Baby", produced and co-written by Spector. The record received unanimously positive reviews and is now considered a landmark recording. Drummer Gillespie announced his departure from the band in October 1985, to concentrate on Primal Scream. He had recorded most of the drums on Psychocandy, with John Moore filling in when Gillespie was unavailable, eventually joining the band to replace him. John Loder also acted as a stand-in drummer when Gillespie was unavailable for live performances. When the band signed to Blanco y Negro in January 1985, there were stories reporting that they had stolen money from managing Director Rob Dickens's jacket and destroyed his office, all untrue but seen as good publicity by manager McGee. In a performance on Belgian television in March 1985, the band did smash the set and the audio equipment, but this was at the request of the TV producer. Such behaviour became expected of the band and many shows culminated with the Reids trashing their equipment, which was often followed by the audience throwing projectiles onto the stage and damaging equipment. On 15 March 1985, the Jesus and Mary Chain played a gig at the North London Polytechnic in front of one of their largest crowds up to that point.
Sources: en.wikipedia.org
tissue In a multicellular organism, a contiguous aggregation of cells held together by a common extracellular matrix and specialized to perform a particular function. Some tissues are composed primarily of a single cell type; others are a heterogeneous mixture of many cell types. Tissues represent a level of multicellular organization between that of individual cells and that of organs, which may be composed of one or more distinct types of tissue.
=== First allegation of domestic abuse === In October 2020, Zverev's ex-girlfriend Olga Sharypova, in an article in Racquet magazine by journalist Ben Rothenberg, accused Zverev of physically and emotionally abusing her over the course of their relationship. Sharypova named multiple instances where Zverev allegedly became violent towards her, including punching her in the face during an argument that took place in the pair's hotel room while Zverev was competing at the 2019 Laver Cup. Zverev denied the allegations and issued a statement after Sharypova's initial accusations: "I very much regret that she makes such statements. Because the accusations are simply not true." A second article by Rothenberg about the allegations was released in August 2021, this time in Slate magazine. The second article picked up Sharypova's story where the first left off. It includes this description of the alleged violence escalating in October 2019:
=== Disorders of plasma protein metabolism === 273 Disorders of plasma protein metabolism 273.0 Polyclonal hypergammaglobulinemia 273.1 Monoclonal paraproteinemia 273.2 Other paraproteinemias 273.3 Macroglobulinemia Waldenström macroglobulinemia 273.8 Other disorders of plasma protein metabolism Atransferrinemia
This is a conceptual leap that was quite different from Ibn al-Nafis' refinement of the anatomy and bloodflow in the heart and lungs." This work, with its essentially correct exposition, slowly convinced the medical world. However, Harvey was not able to identify the capillary system connecting arteries and veins; these were later discovered by Marcello Malpighi in 1661.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.